Strategy Asset Managers LLC Purchases 13,021 Shares of Moderna, Inc. $MRNA

Key Points

• Strategy Asset Managers initiated a Moderna position by purchasing 13,021 shares worth approximately $2.5 million in the third quarter. Institutional investors collectively own 75.33% of the company.
• Moderna insiders sold 118,882 shares valued at approximately $16.9 million over the past three months, including sales by the president and CFO under pre-arranged Rule 10b5-1 plans.
• Analysts maintain a consensus “Hold” rating with a $100.60 price target, well below the stock’s $226.30 opening price, as investors weigh its sharp rally against continued losses and valuation risk.

Strategy Asset Managers LLC acquired a new position in Moderna, Inc. (NASDAQ:MRNA - Free Report) during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund acquired 13,021 shares of the company's stock, valued at approximately $2,507,000.

A number of other hedge funds and other institutional investors also recently modified their holdings of the company. BlackRock Inc. bought a new position in Moderna during the second quarter valued at about $2,142,877,000. Theleme Partners LLP acquired a new position in Moderna during the second quarter worth about $564,272,000. Wellington Management Group LLP grew its holdings in Moderna by 4.4% during the second quarter. Wellington Management Group LLP now owns 2,461,574 shares of the company's stock worth $172,384,000 after acquiring an additional 103,977 shares during the period. Merck & Co. Inc. bought a new stake in Moderna in the second quarter worth about $161,642,545. Finally, Bamco Inc. NY bought a new stake in Moderna in the second quarter worth about $139,317,000. Institutional investors own 75.33% of the company's stock.

Insider Activity

In related news, President Stephen Hoge sold 40,281 shares of the stock in a transaction on Tuesday, September 15th. The stock was sold at an average price of $146.07, for a total value of $5,883,845.67. Following the completion of the transaction, the president owned 1,562,029 shares in the company, valued at $228,165,576.03. This trade represents a 2.51% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Jamey Mock sold 34,836 shares of the stock in a transaction on Thursday, September 10th. The shares were sold at an average price of $134.49, for a total value of $4,685,093.64. Following the completion of the transaction, the chief financial officer owned 59,375 shares of the company's stock, valued at $7,985,343.75. This trade represents a 36.98% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 118,882 shares of company stock valued at $16,862,280 over the last three months. Insiders own 10.80% of the company's stock.

Trending Headlines about Moderna

Here are the key news stories impacting Moderna this week:

• Positive Sentiment: Merck CEO Rob Davis said the companies expect their personalized cancer vaccine to become faster to manufacture as they refine the process. He described production as complex but said Merck and Moderna have reduced it to a highly controlled process, supporting expectations for improved scalability and broader commercial potential. Merck CEO tells CNBC he expects breakthrough cancer vaccine will become faster to make
• Positive Sentiment: Investor enthusiasm around Moderna’s positive cancer-vaccine results, along with its Nasdaq-100 inclusion, has driven a sharp weekly gain and expanded the company’s market capitalization. Moderna’s strength contrasts with weaker recent results from rival BioNTech, reinforcing its perceived leadership in mRNA oncology. MRNA Stock Gains Over $4B in a Week: Time to Buy, Hold or Sell?
• Neutral Sentiment: Moderna will report third-quarter 2026 results on November 6, providing a near-term catalyst. Investors will likely look for updates on revenue trends, cost controls, vaccine demand, clinical progress and the company’s path toward profitability. Moderna to Report Third Quarter 2026 Financial Results
• Negative Sentiment: The rapid rally has increased valuation risk. Investors are questioning whether Moderna’s future cancer-vaccine growth can justify the premium placed on the stock before commercial revenues and profitability are firmly established. MRNA Stock Gains Over $4B in a Week: Time to Buy, Hold or Sell?

Analysts Set New Price Targets

MRNA has been the subject of a number of research analyst reports. CLSA raised shares of Moderna to an "outperform" rating in a report on Friday, August 28th. Singular Research raised shares of Moderna to a "hold" rating in a research note on Wednesday, September 23rd. Bradesco Corretora raised shares of Moderna to an "outperform" rating in a research note on Friday, August 28th. Rothschild & Co Redburn downgraded shares of Moderna from a "neutral" rating to a "sell" rating and boosted their target price for the stock from $40.00 to $81.00 in a report on Thursday, September 3rd. Finally, William Blair started coverage on shares of Moderna in a research note on Friday, August 28th. They set an "outperform" rating for the company. Seven analysts have rated the stock with a Buy rating, fifteen have assigned a Hold rating and four have given a Sell rating to the company. According to MarketBeat, Moderna presently has a consensus rating of "Hold" and a consensus price target of $100.60.

Moderna Stock Performance

MRNA opened at $226.30 on Thursday. The firm has a market cap of $90.35 billion, a PE ratio of -28.32 and a beta of 1.09. The company has a quick ratio of 2.18, a current ratio of 2.29 and a debt-to-equity ratio of 0.09. The business has a fifty day simple moving average of $149.83 and a 200-day simple moving average of $88.67. Moderna, Inc. has a fifty-two week low of $22.28 and a fifty-two week high of $227.46.

Moderna (NASDAQ:MRNA - Get Free Report) last issued its earnings results on Friday, July 31st. The company reported ($1.97) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($2.03) by $0.06. The business had revenue of $145.00 million for the quarter, compared to analysts' expectations of $102.93 million. Moderna had a negative return on equity of 28.30% and a negative net margin of 141.43%. The company's quarterly revenue was up 2.1% on a year-over-year basis. During the same period in the previous year, the firm posted ($2.13) EPS. As a group, equities analysts predict that Moderna, Inc. will post -6.11 EPS for the current fiscal year.

Moderna Profile

Moderna, Inc is a biotechnology company that develops medicines and vaccines using messenger RNA (mRNA) technology. Its platform is designed to instruct cells to produce proteins that can help prevent or treat disease, supporting the company's work across infectious diseases, immuno-oncology, rare diseases, autoimmune conditions, and cardiovascular diseases.

Moderna's commercial products include Spikevax, an mRNA vaccine for COVID-19, and mRESVIA, an mRNA vaccine for respiratory syncytial virus (RSV) in older adults.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.